MS4A1 and Autoimmunity: Analogous to the use of anti-CD20 monoclonal antibodies like Rituximab in other autoimmune conditions, targeting MS4A1 could mitigate the excessive immune response characteristic of KD, thereby ameliorating coronary lesions and improving cardiovascular outcomes.